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Summary A human ovarian carcinoma, IGROV-1, was xenografted into different sites (i.p., s.c., i.v., and
intrasplenically) in nude athymic female mice to investigate the pattern of antitumour efficacy of FAA and
compare it to that of doxorubicin and cisplatin, two established cytotoxic drugs. Ascitic and lung-growing
tumours totally failed to respond to FAA, whereas s.c. and liver-growing tumours were significantly growth
inhibited. This pattern of activity differs from that achieved by the two conventional cytotoxic drugs, which
were active against the IGROV-1 tumour growing in all of the tested sites. These studies indicate that
cytotoxicity is not the major determinant of FAA antitumour efficacy even against human tumour xenografts.
Moreover, the dramatic difference between the sensitivity of lung and liver tumour colonies demonstrates the
great importance of the site of tumour growth for FAA efficacy.
Flavone acetic acid (FAA) is a synthetic flavonoid currently
undergoing clinical trials. It has proved highly effective
against a broad spectrum of subcutaneously growing murine
tumours (Corbett et al., 1986; Plowman et al., 1986) and
against orthotopic colonic tumours in mice (Pratesi et al.,
1988). Preclinical pharmacology revealed a plasma concentra-
tion threshold for drug activity and toxicity in the mouse and
dog (Zaharko et al., 1986). Even though the plasma concen-
trations achievable in man were similar to those active in
murine tumours (Kerr et al., 1987), no responses were ob-
served in a Phase II trial in which potentially therapeutic
doses of FAA were delivered based on pharmacokinetic
studies (Kaye et al., 1988). The discrepancy between clinical
and preclinical FAA activity might be due to specific
differences in drug disposition and metabolism. A lower
clearance of the drug in mice than in man (Cummings et al.,
1989) and a high drug uptake into solid tumours in mice
have been documented (Workman & Ward, 1989).
Several studies support the hypothesis that FAA may act
as a biological response modifier, and that its antitumour
effects may be host-mediated (Smith et al., 1987; Ching &
Baguley, 1987; Hornung et al., 1988; Wiltrout & Hornung,
1988). Reduction of tumour blood flow by FAA has also
been described (Bibby et al., 1989a; Evelhoch et al., 1988;
Zwi et al., 1989). Direct cytotoxicity is likely to have a
marginal role in FAA efficacy, as demonstrated by a low
cytotoxic activity in vitro and by its minimal activity when
delivered i.p. to i.p. growing tumours (Plowman et al., 1986;
Bibby et al., 1987). The site of growth may be critical for
tumour sensitivity and some reports have indicated its impor-
tance in FAA efficacy in the treatment of murine models
(Bibby et al., 1989b).
In this study, the importance of the site of tumour growth
was investigated for a human tumour xenografted in athymic
mice. A human ovarian tumour, IGROV-1, was chosen for
its ability to grow in different sites in nude athymic mice
(Manzotti & Pratesi, 1988), and for its sensitivity to estab-
lished cytotoxic drugs such as doxorubicin and cisplatin. The
aim of the study was to examine possible differences in the
antitumour activity of FAA against IGROV-1 tumour grow-
ing in different sites and to compare the pattern of tumour
response to that produced by conventional cytotoxic agents,




Female 8- 10 week old Swiss nu/nu mice were used through-
out the study. The mice were obtained from Charles River
Laboratories (Calco, Italy) and were maintained in laminar-
air-flow rooms. Sterilised cages, bedding, food and acidified
water were used for maintenance.
Tumour line
IGROV-1 cells, from a human polymorphic and moderately
differentiated ovarian carcinoma in an untreated patient,
were kindly supplied by Dr J. Benard (Institut Gustave
Roussy, Villejuif, France). In our laboratory, IGROV-1 was
adapted to grow as ascites and maintained by i.p. injection of
2 x 106 cells/mouse in 0.4 ml of complete medium F12 (supp-
lemented with 10% fetal calf serum and 5% antibiotics).
Cells were collected from the donor mice using a heparinised
syringe, suspended in sterile saline and centrifuged
(I500 r.p.m. for Omin). The supernatant was removed and
the pellet resuspended in ammonium chloride solution (1:4
v/v) at 4°C for 10 min to lyse red blood cells. After washing
twice in saline, cells were resuspended in complete medium
and their number and viability were determined by trypan
blue exclusion. Median survival time (MST) ranged from 17
to 25 days in different experiments.
Drugs
Flavone acetic acid (FAA) kindly supplied by the National
Cancer Institute, Division of Cancer Treatment (Bethesda,
MD), was dissolved in 5% NaHCO3 solution. Doxorubicin
(DX) and cis-diamminedichloroplatinum (cisplatin, DDP),
kindly supplied by Farmitalia-Carlo Erba (Nerviano, Italy),
were dissolved in water and in saline, respectively. Drugs
were delivered i.p. or i.v. at the volume of 1Oml kg-' of
body weight. The optimal dose of FAA (200 mgkg-') ac-
cording to a schedule of I treatment every 4 days for a total
of 3 times was used throughout the study (Giavazzi et al.,
1988). The two conventional cytotoxic drugs were admini-
stered according to schedules and at doses having proven
efficacy against this tumour in our experience.
Therapy studies
Intraperitoneally growing tumour Mice were injected i.p.
with 2 x 106 cells in 0.4 ml ofcomplete medium. Each experi-
mental group consisted of 9-10 mice. Drug treatment was
started 7 or 8 days after tumour cell inoculum. The percen-
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tage increase in median survival time (MST) in treated over
control mice (T/C%) was used to assess drug effect.
Subcutaneously growing tumour Both flanks of mice were
injected with 2 x 106 cells in 0.2 ml of complete medium.
Between nine and 12 tumours were included in each group.
Drug treatments started when tumours weighed more than
200 mg (day 10 or 14). Tumour weight (TW) was calculated
according to Geran et al. (1972). The percentage tumour
weight inhibition (TWI%) in treated mice was calculated 4
days after the last drug treatment according to the formula:
100-(mean TW in treated/mean TW in controls x 100).
Experimental lung metastases Mice were inoculated via the
tail vein with 5 x 104 viable cells in 0.2 ml of complete
medium. For counting of experimental metastases, mice were
killed at established times (see Table III). After killing, a
15% solution of India ink in phosphate buffered saline (PBS)
was injected into the bronchus of each mice. The removed
lungs were bleached in Fekete's solution (Fekete, 1938)
allowing the metastases to be counted easily as they formed
discrete white nodules on the surface of the lung.
Experimental liver metastases Mice were inoculated in the
spleen with 5 x I05 cells in I ml of medium according to
Lafreniere and Rosenberg (1986). Briefly, mice were anaes-
thetised and their left flanks were prepared for surgery. A
small, cutaneous incision was made and the spleen was
carefully exposed and IGROV-1 cells injected under the
spleen capsule via a 27-gauge needle. One minute after cell
inoculation the spleen was removed and the abdominal cavity
closed. At established times mice were given an injection in
the tail vein of 0.5 ml of a 15% solution of India ink in PBS.
The mice were then killed by cervical dislocation and their
livers were harvested into vials containing Fekete's solution
which bleached the liver, making the tumour deposits
identificable as discrete white nodules against a black back-
ground of normal liver parenchyma.
Drug treatments started on day 3 or 10 in mice bearing
lung and liver metastases. Drug efficacy was assessed by
comparing the median numbers of colonies in treated and in
control mice. Mice without colonies were excluded from
calculation if present in both the control and treated groups
because the absence of the liver colonies might be the result
of failed inoculation. They were however included if present
only in the treated groups because they may then be rea-
sonably ascribed to drug efficacy. The number of mice per
group is reported in the tables.
Statistical comparison
Two tailed Student's t-test and Mann-Whitney Rank test
were used for statistical analysis.
In vitro studies
Cell survival was assessed by tetrazolium dye (MTT) assay
(Alley et al., 1988). In brief, cells were harvested from
exponential-phase maintenance cultures, dispensed into 96-
well culture plates (Costar Plastics 3799) in 100 il volumes
using a repeating pipette (Multipette 4780, Eppendorf) and
treated with 10yd of drug solution or medium for control
wells. Each plate had eight control wells and eight wells for
each dose. After incubation of the microtiter plates for 96 h,
10 tLI of MTT working solution (5 mg ml-') was added to
each culture well and cultures were incubated at 37°C for 4 h.
The culture medium was removed from the wells and re-
placed with 100 il of DMSO, using a multichannel pipette.
The absorbance of each well was measured with a microcul-
ture plate reader (SLT Labinstruments, Austria) at 550 nm
interfaced with an Apple computer. Preliminary experiments
were performed to determine the appropriate seeding number
of the cell line (2.5 x 103 cells/well), after confirming the
linear relationship between the absorbance and number of
cells in the growth curve. The ID50 was defined as the con-
centration of drug that produced 50% reduction of absor-
bance.
Results
The effects of FAA treatment on IGROV-1 tumour xeno-
grafted i.p. or s.c. are presented in Table I. FAA was clearly
inactive against the ascitic tumour, but inhibited the growth
of established subcutaneous tumours.
The effects of FAA on experimental metastases of
IGROV-1 tumour in lungs or in liver are reported in Table
II. It can be seen that the drug is inactive against lung
metastases when delivered either early (day 3) or late (day 10,
at which time histological evidence of tumour nodules in the
lungs was observed). On the contrary, FAA clearly reduced
the number of liver colonies (P<0.01 compared to the con-
trol mice) even when the drug treatments started at day 10.
The sensitivity to two conventional cytotoxic drugs, i.e.
doxorubicin (DX) and cisplatin (DDP), of IGROV-1 tumour
growing in various sites, is reported in Table III. IGROV-1
tumours respond to the two drugs in all the sites even though
at different levels.
The results of the in vitro studies (Figure 1) clearly showed
FAA to be less cytotoxic than DX against IGROV-1 cells,
the ID50 values being 20 and 0.05 Agml-', respectively.
Discussion
The results obtained in the treatment of the human IGROV-
1 tumour clearly showed a site-dependent sensitivity to FAA.
Significant antitumour effects occurred for tumours growing
s.c. and in liver whereas i.p.- and lung-growing tumours
failed to respond. In contrast to the inactivity of FAA,
IGROV-l cells growing i.p. did respond to locoregional
treatment with two conventional cytotoxic drugs, thus
confirming the marginal contribution of a direct cytotoxicity
in the mechanism of action of FAA. These in vivo results are
consistent with the observation that in vitro very high con-
centrations of FAA are required for cytotoxic effects on these
tumour cells.
For s.c. growing murine tumours, the sensitivity has been
possibly ascribed to a Tumour Necrosis Factor (TNF)-like
action of FAA (Smith et al., 1987; Finlay et al., 1988), and
recently we have demonstrated a critical role of TNF in FAA
activity against murine colon tumour # 26 (Pratesi et al.,
1990). However, the possibility that FAA antitumour efficacy
on this human carcinoma is mediated through TNF seems
unlikely, since haemorrhagic necrosis was not visible in the
tumours 24 h after FAA treatment. Moreover, T cells repre-
sent an important component of FAA efficacy (Pratesi et al.,
1990) and this mechanism may not be operating in nude
mice, genetically lacking ofT cells. Therefore, the basis of the
activity of the drug against this human tumour xenografted
s.c. in nude mice is unclear, but may be due to an effect on
tumour blood flow as described in other tumour models
(Evelhoch et al., 1988; Bibby et al., 1989a; Zwi et al., 1989).
The most striking finding of this study was the dramatic
difference in the efficacy of FAA against tumour cells grow-
ing in lungs or in the liver, whereas DX and DDP were




site (tumours) Route Days %oT/Ca %TWP P<
i.p. 10 i.p. 7,11,15 97 0.2
s.c. (11) i.v. 10,14,18 70 0.05
(7) 14,18,22 65 0.05
a% Increase ofmedian survival time (MST) in treated (T) mice over
control (C) mice. MST in controls was 20 days. b% Tumour weight
inhibition in treated mice compared to control mice, measured 4 days
after the last treatment.FLAVONE ACETIC ACID AND SITE OF TUMOUR GROWTH 73
Table II FAA (200 mg/kg, i.v.) activity against experimental metastases of IGROV-1
human tumour
Metastases Days of Day of No. ofmice with Median no."
in treatment evaluation metastases/total ofmetastases P<
Lung - 28 7/8 31 (12-147)
3,7,11 28 7/9 26 (1-216) 0.1
- 35 6/6 172.5 (29-250)
10,14,18 35 7/7 188 (2-250) 0.2
Liver - 24-28b 12/12 200 (2-250)
10,14,18 24-28 8/11 29 (0-250) 0.01
aOnly numbers ofmetastatic deposits<250could be reliably counted; organs with deposit
numbers> 250 were assigned an empirical number of 250. Ranges of values are given in
parentheses. bData pooled from two experiments.
Table III Sensitivity of IGROV-1 human tumour to standard
cytotoxic drugs
Tumour Dose Treatment
site Drug mgkg-' Route Days Response P<
i.p. DX 7.5 i.p. 7,14,21 208a 0.01
s.c. DX 5 i.v. 8,12,14 39b 0.1
lung DX 5 i.v. 3,7,11 OC 0.1
(0-62)
liver DX 5 i.v. 10,14,18 12d 0.2
(0-81)
i.p. DDP 6 i.p. 7,14,21 219a 0.01
s.c. DDP 4 i.v. 14,18,22 65b 0.05
lung DDP 4 i.v. 3,7,11 OC 0.05
(0-6)
a% Increase ofmedian survival time (MST) in treated (T) mice over
control (C) mice. MST in C was 20 days. b% Tumour weight inhibition
intreatedmicecompared tocontrolmice,4daysafterthelasttreatment.
CMedian number ofmetastases in lungs. Ranges of values are given in
parentheses. Controls: 59 (7-94). dMedian number of metastases in
liver. Ranges ofvalues are given in parentheses. Controls: 250 (2-250).
active at both sites. The reasons for this difference remain
unclear. Even though a cytotoxic effect of FAA per se seems
unimportant in its antitumour efficacy, the high response
achieved against liver colonies could be the result of meta-
bolic activation of the drug to more cytotoxic compounds as
observed in vitro (Chabot et al., 1989). Differences in meta-
bolism between mouse and man (Cummings et al., 1989)
must be considered, and may explain the lack of activity in
17 patients with liver metastasis (Kerr et al., 1989). As an
alternative explanation of the different effect of FAA against
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Figure 1 IGROV-1 cells were exposed to drugs for 96 h. Cyto-
toxicity was evaluated by the tetrazolium derivative reduction
(MTT) assay. DX:0; FAA:0.
threshold drug level at the tumour site is required for
antitumour action. In fact, a higher peak level and area
under the curve values (Damia et al., 1988), as well as a
higher increase in NK activity (Wiltrout et al., 1988) in liver
than in lungs of mice have been described.
In conclusion, in contrast to the effects of two conven-
tional cytotoxic drugs, which were effective against IGROV-1
ovarian tumour in all the examined sites, the activity of FAA
was critically dependent on the site of tumour growth in-
dicating that mechanisms other than a direct cytotoxicity are
determinants of FAA activity even against human xeno-
grafts.
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